DiaMedica Therapeutics Inc. (NasdaqCM: DMAC)
Health Care · Biotechnology · US
$6.52
0.00% today · +6.7% 1Y
DiaMedica Therapeutics Inc. (NasdaqCM: DMAC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $351.60M and employs 35 people.
Over the last twelve months the share price has gained 6.7%, trading between 5.14 and 10.42.
Tweenvest scores DiaMedica Therapeutics Inc. across four factors: quality 29/100. Its strongest factor is quality.
DMAC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $351.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.72
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- $10.42
- 52-week low
- $5.14
- Avg volume (3M)
- —
- Shares outstanding
- 53.93M
- Employees
- 35
- Next earnings
- —
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
- ISIN
- CA25253X2077
- Founded
- 2000
- Listed since
- Aug 3, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.